Literature DB >> 12174736

Pharmacotherapy to sustain the fully remitted state.

Sidney Kennedy1, Roger McIntyre, Angelo Fallu, Raymond Lam.   

Abstract

Full remission should be the goal of antidepressant therapy; anything less leaves the patient with residual symptoms and an increased risk of relapse and recurrence. Most antidepressant agents offer similar rates of response, but there are some differences in the ability of different agents to promote a full remission. The greatest chance of achieving full remission occurs early in the course of treatment; thus, initial antidepressant strategies should be those that have the greatest therapeutic potential. Other strategies that may help improve the chances of achieving full remission include optimizing drug dosages and using combination and augmentation strategies. Failure to achieve full remission and early discontinuation of antidepressant therapy have been associated with a greater incidence of relapse and recurrence. Continued antidepressant therapy has clearly been shown to effectively reduce the probability of relapse and recurrence by about half compared with placebo. Therefore, once a patient achieves remission, it is important to continue the same antidepressant therapy for at least 6-12 months and, for many patients, considerably longer. Medication should continue at the dose that was initially effective because using low-dose maintenance therapy appears to decrease the protective benefits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174736      PMCID: PMC161661     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  65 in total

1.  The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.

Authors:  C Ballús; G Quiros; T De Flores; J de la Torre; D Palao; L Rojo; M Gutiérrez; L Casais; Y Riesgo
Journal:  Int Clin Psychopharmacol       Date:  2000-01       Impact factor: 1.659

Review 2.  Recognition and management of depression in general practice: consensus statement.

Authors:  E S Paykel; R G Priest
Journal:  BMJ       Date:  1992-11-14

3.  The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression.

Authors:  C A Melfi; A J Chawla; T W Croghan; M P Hanna; S Kennedy; K Sredl
Journal:  Arch Gen Psychiatry       Date:  1998-12

4.  Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

Authors:  R J Kavoussi; R T Segraves; A R Hughes; J A Ascher; J A Johnston
Journal:  J Clin Psychiatry       Date:  1997-12       Impact factor: 4.384

5.  Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.

Authors:  M Bauer; T Bschor; D Kunz; A Berghöfer; A Ströhle; B Müller-Oerlinghausen
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

6.  Future imperfect: the long-term outcome of depression.

Authors:  P G Surtees; C Barkley
Journal:  Br J Psychiatry       Date:  1994-03       Impact factor: 9.319

7.  Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

Authors:  L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

8.  The course of affective disorders.

Authors:  J Angst
Journal:  Psychopathology       Date:  1986       Impact factor: 1.944

9.  Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.

Authors:  J Lonnqvist; S Sihvo; E Syvälahti; H Sintonen; O Kiviruusu; H Pitkanen
Journal:  Acta Psychiatr Scand       Date:  1995-03       Impact factor: 6.392

10.  Cost utility analysis of maintenance treatment for recurrent depression.

Authors:  M S Kamlet; N Paul; J Greenhouse; D Kupfer; E Frank; M Wade
Journal:  Control Clin Trials       Date:  1995-02
View more
  9 in total

Review 1.  Remission from depression : a review of venlafaxine clinical and economic evidence.

Authors:  Donald Han; Edward C Y Wang
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs.

Authors:  Julie L Priest; C Ron Cantrell; Jack Fincham; Christopher L Cook; Steven P Burch
Journal:  Popul Health Manag       Date:  2010-12-13       Impact factor: 2.459

3.  Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

Authors:  Arif Khan; Anjana Bose; George S Alexopoulos; Carl Gommoll; Dayong Li; Chetan Gandhi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 4.  Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.

Authors:  Sidney H Kennedy; Sakina J Rizvi
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 5.  Future prospects in depression research.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

6.  Poor response to treatment: beyond medication.

Authors:  César Carvajal
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

7.  Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.

Authors:  Debanjali Mitra; Paul Hodgkins; Linnette Yen; Keith L Davis; Russell D Cohen
Journal:  BMC Gastroenterol       Date:  2012-09-24       Impact factor: 3.067

8.  Exploring the role of drug-metabolising enzymes in antidepressant side effects.

Authors:  Karen Hodgson; Katherine E Tansey; Rudolf Uher; Mojca Zvezdana Dernovšek; Ole Mors; Joanna Hauser; Daniel Souery; Wolfgang Maier; Neven Henigsberg; Marcella Rietschel; Anna Placentino; Ian W Craig; Katherine J Aitchison; Anne E Farmer; Richard J B Dobson; Peter McGuffin
Journal:  Psychopharmacology (Berl)       Date:  2015-03-12       Impact factor: 4.530

Review 9.  The Shared Decision-Making Process in the Pharmacological Management of Depression.

Authors:  Malcom Hopwood
Journal:  Patient       Date:  2020-02       Impact factor: 3.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.